HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo 
HSBC Plans Deep UK Wealth Job Cuts in AI Push 
FDA Weighs Safety Standards for Psychedelic Therapies 
German Industrial Orders Plunge 10.6% in August 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Gold Prices Rise as Dollar Weakens, Treasury Yields Ease 
Wall Street Rises as Oil Prices Ease, Nasdaq Hits Record 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Iran Tanker Attacks Surge as Hormuz Oil Flows Near Prewar Levels 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Gold Prices Slip as Strong Dollar and High Treasury Yields Weigh 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Ripple Expands Brevan Howard Deal With Prime Brokerage Services 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Add as a preferred source on Google
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
